[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597038":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":55,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":30,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":30,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":38,"whyStopped":30,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Empagliflozin","EXPERIMENTAL","Empagliflozin 25 mg\u002Fday",[13],"Drug: Empagliflozin 25 MG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Empagliflozin 25 MG","A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.",[9],[21],"Jardiance",[23],{"name":24,"affiliation":5,"role":25},"Ralph DeFronzo, MD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","210-567-6691",null,"defronzo@uthscsa.edu",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":34},"Aurora Merovci, MD","merovci@uthscsa.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Texas Diabetes Institute\u002FUH","RECRUITING","San Antonio","Texas","78229-3900","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-98.49363,29.42412,{"lat":48,"lon":47},[51,53,54],{"name":24,"role":28,"phone":52,"phoneExt":30,"email":31},"210-358-7200",{"name":33,"role":28,"phone":29,"phoneExt":30,"email":34},{"name":24,"role":25,"phone":30,"phoneExt":30,"email":30},{"type":56,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[58],{"name":59,"class":60},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100597038","early-phase-1-sglt2i-hepatic-glucose-production-and-sns-100597038",false,"NCT07053293","SGLT2i, Hepatic Glucose Production, and SNS","Protocol II: SGLT2i, Hepatic Glucose Production, and Sympathetic Nervous System (SNS)","Patients with T2D\n\nInclusion Criteria:\n\n* Ages 30-75\n* BMI (Body Mass Index) 21-45 kg\u002Fm2\n* HbA1c = 7.0-11%\n* eGFR (estimated glomerular filtration rate)\\> 60 ml\u002Fmin\u002F1.73m2\n* Blood Pressure (BP)≤160\u002F90 mmHg\n* Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH\u002FT4 (thyroid\u002Fthyroxine hormone), EKG (electrocardiogram), and urinalysis (UA)\n* Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program\n* Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas\u002FMetformin (Sulfo\u002FMET)\n* Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment.\n* Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment.\n* SGLT2 inhibitors must be discontinued at least two months prior to study enrollment.\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded.\n* Patients taking medications other than Sulfonylureas\u002FMetformin (SU\u002FMET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \\*\n* Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \\\u003C 60 are excluded\n* Women of childbearing potential are excluded unless they are taking\u002Fusing appropriate contractive medications\u002Fdevices \\* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor.\n\nIf their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%.\n\nHbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase.\n\nAfter two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.","ALL","30 Years","75 Years",{"count":72,"type":73},22,"ESTIMATED","INTERVENTIONAL",[76],"EARLY_PHASE1","In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. Principal Investigator (PI) will conduct five distinct experiments to test this hypothesis in patients with T2D.\n\nTo examine the role of the SNS on the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D by comparing the effect of empagliflozin versus empagliflozin plus propranolol.",[79],"Type 2 Diabetes",[81,82,83,84,85],"Endogenous glucose production","Ketogenesis","Gluconeogenesis","Lipolysis","Norepinephrine turnover","2026-07-15",{"date":88,"type":89},"2026-07-17","ACTUAL",{"date":91,"type":89},"2025-01-07",{"date":93,"type":73},"2027-06-30",{"name":5,"class":6},1]